The Pathology Report and Tissue Testing
At a Glance
An axillary lipoma pathology report distinguishes a benign conventional lipoma from an atypical lipomatous tumor. The diagnosis may combine microscope findings, MDM2 FISH, specimen type, and margins; a single test result should not be interpreted alone.
When a piece of a fatty mass is removed—either through a small needle biopsy or a full surgery—it is sent to a pathologist. These doctors study the tissue under a microscope to confirm exactly what the mass is made of. For a lump in the armpit, the most critical job of the pathologist is to distinguish a standard, harmless lipoma from a more complex growth that might require closer monitoring.
Under the Microscope: Lipoma vs. ALT
To the naked eye, most fatty tumors look like yellowish blobs of grease. However, under the microscope, the pathologist looks for specific “cellular signatures” [1].
- Conventional Lipoma: This is the most common result. It consists of mature adipocytes (fat cells) that look exactly like normal body fat. The cells are uniform in size, and there is no “atypia”—meaning the cells don’t look weird or aggressive [1][2].
- Atypical Lipomatous Tumor (ALT): Also known as Well-Differentiated Liposarcoma (WDLPS), this is a “low-grade” tumor. They are closely related entities in the same biologic spectrum, but ALT is commonly used for surgically amenable peripheral tumors and WDLPS is often used for central or retroperitoneal disease. The pathologist looks for nuclear atypia—enlarged or darkened centers (nuclei) within the fat cells or the surrounding “scaffolding” (stroma) [1][3].
In the armpit, identifying an ALT is important because these tumors are locally aggressive. While they rarely spread to other parts of the body, they have a risk of local recurrence and dedifferentiation if they aren’t removed completely [3][4].
The “Gold Standard” Test: MDM2 FISH
Sometimes, the cells look so much like normal fat that a pathologist cannot be 100% sure just by looking. In these cases, they perform a molecular test called FISH (Fluorescence In Situ Hybridization) to look for MDM2 amplification [5][6].
Think of your DNA like a library. In a normal lipoma, there are two “books” (copies) of the MDM2 gene. In an ALT/WDLPS, the tumor has “amplified” this gene, creating dozens or hundreds of copies [5].
- Positive MDM2 Result: If the test shows a high MDM2-to-CEP12 ratio, it supports the diagnosis of an ALT/WDLPS. A ratio threshold (like 2.0 or higher) may be used by a particular laboratory to call amplification [7][8].
- Negative MDM2 Result: This suggests the mass is a benign lipoma. However, MDM2 results must be interpreted with morphology, assay criteria, and specimen quality; a negative result does not absolutely exclude an atypical lesion or sampling error [5][6].
Rely on the integrated pathology diagnosis, which combines molecular and physical features, rather than a single ratio. Other tests, like PLAG1 rearrangements, are sometimes used to identify specific subsets of adult lipomas [9][10].
Your Pathology Report Checklist
Depending on the specimen, diagnosis, and local practice, your report may include:
- Specimen Type: Does it say “Core Biopsy” (a small sample) or “Excision” (the whole lump)?
- Tumor Dimensions: The size of the mass. Distinguish the size of a core specimen from the total tumor size.
- Histologic Diagnosis: The specific name of the tumor (e.g., “Conventional Lipoma,” “Spindle Cell Lipoma,” or “Atypical Lipomatous Tumor”).
- Atypia and Mitoses: A description of whether the cells look unusual and how fast they are dividing (mitotic rate) [11][12].
- MDM2 Status: For suspected or confirmed atypical or malignant tumors, whether MDM2 FISH testing was performed [6].
- Margins: For an excised atypical tumor, the report may state if the edges are “clear” (negative) or “involved” (positive). Detailed margin expectations are reserved for suspected or confirmed atypical tumors [13][12].
If your results are “equivocal” (unclear), it is a good idea to ask if the slides can be reviewed by a specialist in soft tissue pathology [6][14].
Common questions in this guide
What is the difference between a conventional lipoma and an atypical lipomatous tumor?
What does a positive MDM2 FISH result mean for an armpit fatty tumor?
Can a negative MDM2 test rule out an atypical lipomatous tumor?
What information should I look for in my axillary lipoma pathology report?
Could a core biopsy miss a more complex part of the mass?
What do clear or involved margins mean after an axillary mass is removed?
One line in your results can change your plan.
An MDM2 FISH result can support an atypical tumor diagnosis, which may call for closer monitoring with your specialist. We check your results against the latest research to help you prepare for what’s next.
Get notified when new evidence is published on axillary lipoma.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (14)
- 1
Management challenges of a giant retroperitoneal liposarcoma: A case report and review of the literature.
Mremi A, Macheku GS, Mondea AP, et al.
International journal of surgery case reports 2024; (125()):110629 doi:10.1016/j.ijscr.2024.110629.
PMID: 39566432 - 2
Adipocyte size variability in benign and malignant lipomatous tumors and morphologic mimics: a quantitative definition using digital pathology.
Bean GR, Wen KW, Horvai AE
Human pathology 2018; (72()):52-58 doi:10.1016/j.humpath.2017.10.030.
PMID: 29128479 - 3
Biology and Management of Deep-seated Atypical Lipomatous Tumor of the Extremities.
Nishio J, Nakayama S, Chijiiwa Y, Aoki M
Anticancer research 2023; (43(10)):4295-4301 doi:10.21873/anticanres.16624.
PMID: 37772567 - 4
[A case report of recurrent giant intermuscular lipoma in the temporal region].
Zhan L, Xu B, Bian P
Lin chuang er bi yan hou tou jing wai ke za zhi = Journal of clinical otorhinolaryngology head and neck surgery 2026; (40(4)):408-411 doi:10.13201/j.issn.2096-7993.2026.04.014.
PMID: 41927101 - 5
MDM2 RNA In Situ Hybridization for the Diagnosis of Atypical Lipomatous Tumor: A Study Evaluating DNA, RNA, and Protein Expression.
Kulkarni AS, Wojcik JB, Chougule A, et al.
The American journal of surgical pathology 2019; (43(4)):446-454 doi:10.1097/PAS.0000000000001199.
PMID: 30520819 - 6
Atypical lipomatous tumor/well differentiated liposarcoma and related mimics with updates. When is molecular testing most cost-effective, necessary, and indicated?
Kilpatrick SE
Human pathology 2024; (147()):82-91 doi:10.1016/j.humpath.2023.12.005.
PMID: 38135062 - 7
Automated Bright-Field Dual-Color In Situ Hybridization for MDM2: Interobserver Reproducibility and Correlation With Fluorescence In Situ Hybridization in a Series of Soft Tissue Consults.
Zhang G, Lanigan CP, Goldblum JR, et al.
Archives of pathology & laboratory medicine 2016; (140(10)):1111-5 doi:10.5858/arpa.2015-0249-OA.
PMID: 27684983 - 8
Low-Level MDM2 Amplification by FISH: An Institutional Experience With a Diagnostic Dilemma.
Naous R, Hegazy S
International journal of surgical pathology 2025; (33(4)):891-900 doi:10.1177/10668969241295353.
PMID: 39563528 - 9
Recurrent 8q11-13 Aberrations Leading to PLAG1 Rearrangements, Including Novel Chimeras HNRNPA2B1::PLAG1 and SDCBP::PLAG1, in Lipomatous Tumors.
Panagopoulos I, Andersen K, Gorunova L, et al.
Cancer genomics & proteomics 2023; (20(2)):171-181 doi:10.21873/cgp.20372.
PMID: 36870688 - 10
New molecular insights into the pathogenesis of lipoblastomas: clinicopathologic, immunohistochemical, and molecular analysis in pediatric cases.
Lopez-Nunez O, Alaggio R, Ranganathan S, et al.
Human pathology 2020; (104()):30-41 doi:10.1016/j.humpath.2020.07.016.
PMID: 32692992 - 11
"Enhancing Liposarcoma Prognosis - A New Predictive Scoring System Integrating Histopathological Insights".
Ciongariu AM, Țăpoi DA, Dumitru AV, et al.
Cancer management and research 2025; (17()):331-348 doi:10.2147/CMAR.S504889.
PMID: 39990278 - 12
A Very Rare Case of Predominantly Well-Differentiated Primary Male Breast Liposarcoma With Focal Dedifferentiation and Histologically Confirmed Pectoral Muscle Invasion.
Yildiz MA, Gurbuz DC, Öz B, et al.
Cureus 2026; (18(9)):e115950 doi:10.7759/cureus.115950.
PMID: 42852095 - 13
Quality of Histopathological Reporting in Breast Cancer: Results From Four South African Breast Units.
Toma A, O'Neil D, Joffe M, et al.
JCO global oncology 2021; (7()):72-80 doi:10.1200/GO.20.00402.
PMID: 33434068 - 14
Fluorescence In Situ Hybridization for MDM2 Amplification as a Routine Ancillary Diagnostic Tool for Suspected Well-Differentiated and Dedifferentiated Liposarcomas: Experience at a Tertiary Center.
Thway K, Wang J, Swansbury J, et al.
Sarcoma 2015; (2015()):812089 doi:10.1155/2015/812089.
PMID: 25810689
This page is for informational purposes only and does not constitute medical advice. Your pathologist or treating clinician should interpret your axillary mass results and advise you about follow-up.